Get the latest news, insights, and market updates on STIM (Neuronetics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Neuronetics: Q3 Earnings Snapshot
STIM) on Tuesday reported a loss of $9 million in its third quarter. The Malvern, Pennsylvania-based company said it had a loss of 13 cents per share. The medical device company focused on psychiatric disorders posted revenue of $37.3 million in the period. Nov 4, 2025 - $STIM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a mater Oct 31, 2025 - $STIM
Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence
New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA ClinicsMALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced an exclusive three-year agreement with Elite DNA Behavioral Health Oct 30, 2025 - $STIM
Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call
MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. T Oct 21, 2025 - $STIM
New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)
Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that New York State Sep 17, 2025 - $STIM
Neuronetics, Inc. (STIM) Positions as Neurohealth Leader with Adolescent Breakthrough
We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Neuronetics, Inc. is placed sixth among them. Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company specializing in neurohealth solutions, including its flagship NeuroStar Advanced Therapy System, a leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder and obsessive-compulsive […] Sep 2, 2025 - $STIM
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of -87.50% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 5, 2025 - $STIM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple